AB Science received FDA authorization to initiate Phase 1/II trial of AB8939 in the treatment of acute myeloid leukemia
November 22, 2021 12:20 ET
|
AB Science
PRESS RELEASE AB SCIENCE RECEIVES U.S. FOOD AND DRUG ADMINISTRATION (FDA) AUTHORIZATION TO INITIATE PHASE I/II TRIAL OF AB8939 IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) AB8939 IS A NEW...
Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
November 22, 2021 07:10 ET
|
Apollomics, Inc.
FOSTER CITY, Calif. and SHANGHAI and HANGZHOU, China, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono-...
Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia
September 16, 2021 07:30 ET
|
Intellia Therapeutics, Inc.
NTLA-5001 is Intellia’s first ex vivo candidate using its proprietary cell engineering process for the treatment of cancer to enter clinical studyNTLA-5001 targets Wilms’ Tumor 1 (WT1), an...
Rafael Pharmaceuticals Announces Positive Preplanned Interim Futility Analysis of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)
July 01, 2021 08:00 ET
|
Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., July 01, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced positive...
Aprea Therapeutics Receives FDA Orphan Drug Designation for Eprenetapopt for the Treatment of Acute Myeloid Leukemia (AML)
April 08, 2021 11:15 ET
|
Aprea Therapeutics
BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Rafael Pharmaceuticals Crosses Enrollment of 150 Patients in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)
March 30, 2021 09:00 ET
|
Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., March 30, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced...
Apollomics, Inc. Announces Successful Enrollment of First Patient Into Phase 1 Clinical Trial of APL-106 (Uproleselan Injection) in China
March 04, 2021 07:10 ET
|
Apollomics, Inc.
FOSTER CITY, Calif. and HANGZHOU, ZHEJIANG, China, March 04, 2021 (GLOBE NEWSWIRE) -- Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono-...
Acute Myeloid Leukemia Pipeline Assessment 2021 report covers Unmet Needs, Key Opportunities, and Major Players
February 15, 2021 20:00 ET
|
DelveInsight Business Research LLP
Los Angeles, USA, Feb. 15, 2021 (GLOBE NEWSWIRE) -- Acute Myeloid Leukemia Pipeline Assessment 2021 report covers Unmet Needs, Key Opportunities, and Major Players DelveInsight highlights recent...
UPDATE - Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leukemia (AML)
December 15, 2020 11:09 ET
|
Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today...
Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leukemia (AML)
December 15, 2020 09:00 ET
|
Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today...